Hel

Rapid Flu Tests May Prove Especially Helpful This Season

On October 5, Chiron Corporation notified the CDC that none of its influenza vaccine (Fluvirin) would be available for distribution in the United States for the current influenza season. In the wake of this sudden removal of nearly half of the anticipated American vaccine supply, medical officials and the general public have grown increasingly alarmed about the scarcity of vaccine and the ris...

Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer

- First prospective biomarker trial in non-small cell lung cancer - LOS ANGELES, July 09, 2007 /PRNewswire-FirstCall/ -- ResponseGenetics, Inc. today announced that positive Phase III clinicaldata published in the July 1 issue of the Journal of ClinicalOncology suggests that low expression of the biomarkerExcision-Repair Cross-Complementing 1 (ERCC-1) in patient biopsieswith advanced non-...

ApoCell's Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy

HOUSTON--(BUSINESS WIRE)--Jun 7, 2007 - ApoCell, Inc. presented theresults of a study conducted by researchers at the University ofChicago and ApoCell at the 2007 annual meeting of the AmericanSociety of Clinical Oncology (ASCO) held in Chicago in early June.The study showed that ApoCell's advanced pharmacodynamic biomarkerassay technology provides reliable predictive data of clinicalrespon...

Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data

Nine out of 10 non-diabetic patients treated withExforge achieved recommended blood pressure goals[1] Additional average decrease of 20 mmHg insystolic blood pressure observed in patients taking Exforge overreductions seen with previous monotherapy[1] Nearly 70% of those with high blood pressure notat treatme...

Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show

BOSTON--(BUSINESS WIRE)--May 1, 2007 - Significantly more patientstreated with Pfizer's Lyrica reduced their pain by 50 percent ormore compared with placebo, according to study results presentedtoday at the American Academy of Neurology annual meeting.Clinically, this outcome would equate to a patient with severe painreporting a reduction to mild to moderate pain. Fibromyalgia is one of t...

Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention

BOTHELL, Wash., April 18, 2007 /PRNewswire-FirstCall/ -- HelixBioMedix, Inc. today announced that Timothy Falla, Ph.D, ChiefScientific Officer, will present an update on the company's newgeneration of small molecule peptide (lipohexapeptide) technologyat the BIO International Convention. The convention will take placeat the Boston Convention & Exhibition Center in Boston, MA fromMay...

Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting

BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ --ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate,may have potential as a chemopreventive agent, according toworld-renowned mesothelioma researcher Michele Carbone M.D., Ph.D.,at this week's American Association for Cancer Research (AACR)Annual Meeting. In a series of poster presentations, Dr. Carbone highlig...

NIDA Study Identifies Genes That Might Help Some People Abstain from Smoking

BETHESDA, Md., April 2, 2007--Scientists supported by theNational Institute on Drug Abuse (NIDA), part of the NationalInstitutes of Health, have for the first time identified genes thatmight increase a person's ability to abstain from smoking. Thebreakthrough research was conducted by Dr. George Uhl at NIDA'sIntramural Re...

Helix BioPharma Corp. Announces Positive Phase II Clinical Results with its Topical Interferon Alpha-2b

AURORA, ON, March 30, 2007 /PRNewswire-FirstCall/ - Helix todayannounced positive results from its phase II clinical study of itsTopical Interferon Alpha-2b in women with human papilloma virus(HPV) induced low-grade cervical lesions. The study showed a clinically efficacious response to treatmentin nearly half of the treated patients. In addition, the pr...

Study Suggests Invega Helps Patients With Schizophrenia Maintain Symptom Control

52-Week Trial Maintained Improvement in Personal and SocialPerformance COLORADO SPRINGS, Colo., March 30, 2007 /PRNewswire/ --Longer-term treatment with INVEGA(TM) (paliperidone)Extended-Release Tablets, a new once daily oral medication forschizophrenia, helped many patients effectively control theirsymptoms and maintain their improvements in personal and socialfunctioning....

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Researchat Helix BioPharma Corp., a developer of novel cancer therapeutics,will be presenting a scientific poster at the Fourth InternationalConference on Tumor Microenvironment, which runs from March 6th to10th in Florence, Italy. The conf...